Cite
HARVARD Citation
Choi, I. et al. (2021). A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. European journal of cancer. pp. 288-295. [Online].